Both presenters for the ACR: Year in Review agreed that 2019 was a year where the field of rheumatology exploded, both in clinical updates and basic science research, as more people enter the field and technology helps harness “big data.”
The session focused on the clinical manifestations of irAEs associated with cancer immunotherapies, including the molecular pathogenesis, tools that aid early diagnosis and treatment, and shared mechanisms and relationships with primary autoimmune diseases.
“Historically, we’ve thought about how we better treat (lupus), how we make patients feel better … But if we want to eliminate lupus, we need to understand early events and how we can stop things before it’s too late,” said Judith James, MD, PhD.
“I would suggest that our members demonstrate their enthusiasm for the field and reach out to young students and trainees — the younger they are when we reach out to them, the better. Medical school would be a great time. There’s nothing more important than an enthusiastic mentor,” she said.
The rapidly changing world of medical apps has made for some exciting breakthroughs, but generally, the rheumatology community hasn’t seen as many of these advances because it has been slower to adopt these technologies.
Approaches and treatments for the metabolic bone disorders rheumatologists are most likely to see, hypophosphatasia, osteomalacia, and primary hyperthyroidism, are changing, and the outlook on all three is improving.